Health Care • Biotechnology: Pharmaceutical Preparations
$3.21 ▲ +0.14
(+4.56%)
MKT CAP: $5.0M • VOL: 50.1K
52W L $2 52W H $60
ROARABLE / RQD
D- • 43/100
PIOTROSKI
1 / 9
APUS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.9M | -$1.3M | -$747.4K |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$6.0M | -$1.4M | -$777.7K |
| EBITDA (Normalized) | -$11.9M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.9M | -$733.5K | -$627.8K |
| Capital Expenditures (CapEx) | $57.3K | — | — |
| Free Cash Flow (FCF) | -$9.0M | -$733.5K | -$627.8K |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -6.2% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.6M | $3.5K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $153.3M | -$1.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR APUS.